<DOC>
	<DOC>NCT00413270</DOC>
	<brief_summary>This study will evaluate the safety of nilotinib in adult patients with imatinib-resistant or -intolerant CML-blast crisis, CML-accelerated phase or CML-chronic phase when treated with nilotinib. Patients will be provided access to nilotinib until the drug is available on the market.</brief_summary>
	<brief_title>Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Imatinib resistant or intolerant Philadelphia chromosome positive CML in blast crisis Imatinib resistant or intolerant Philadelphia chromosome positive CML in accelerated phase Imatinib resistant or intolerant Philadelphia chromosome positive CML in chronic phase CML patients who have been treated with an investigational tyrosine kinase inhibitor who otherwise meet the definition of imatinib resistance or intolerance World Health Organization (WHO) performance status â‰¤ 2 Cytopathologically confirmed central nervous system (CNS) infiltration Impaired cardiac function Use of therapeutic coumarin derivatives Acute chronic liver or renal disease unrelated to tumor Other uncontrolled medical conditions Treatment with hematopoeitic colony stimulating factors Treatment with medications that have potential to prolong the QT interval Another malignancy currently clinically significant or requires active intervention Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Imatinib resistant,</keyword>
	<keyword>Imatinib intolerant,</keyword>
	<keyword>CML- blast crisis,</keyword>
	<keyword>CML- Accelerated phase,</keyword>
	<keyword>CML- chronic phase,</keyword>
	<keyword>nilotinib,</keyword>
	<keyword>Chronic myelogenous leukemia,</keyword>
	<keyword>blast crisis,</keyword>
	<keyword>accelerated phase,</keyword>
	<keyword>chronic phase</keyword>
</DOC>